Anti-human IL-4R alpha recombinant monoclonal antibodies
Dupilumab biosimilar antibodies comprise the variable region of Dupilumab and either the same constant region of Dupilumab or a different one with distinct effector functions (ADCC and ADCP).
Dupilumab which contains a human IgG4 (S228P) constant region displays low effector functions; the other biosimilar features an IgG1 constant region that exhibits high effector functions. These two non-therapeutic antibodies can be used for the comparative study of the complex interactions induced by their Fc domains.
Key features
- Each lot is functionally tested and validated
- Choice of different isotypes for high/low effector functions
- The complete sequence of the antibody constructs has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Dupilumab background
Dupilumab is a therapeutic, fully human IgG4 (S228P) monoclonal antibody (mAb) that targets the human IL-4 receptor alpha subunit (CD124) of the type I and type II IL-4 receptors. It acts as a receptor antagonist and blocks the signaling of both IL-4 and IL-13. This antibody contains an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules. Dupilumab has shown efficacy across multiple Th2 cellular inflammatory disorders and is approved for treating asthma, atopic dermatitis, and chronic sinusitis. Due to its favorable safety profile and established clinical use, dupilumab holds significant promise for amending treatment options for a plethora of dermatologic conditions.
